Wegovy
FDA Announces Availability of All Doses of Novo Nordisk’s Ozempic and Wegovy
FDA, Novo Nordisk, Ozempic, Wegovy, drug shortage, semaglutide, obesity treatment, type 2 diabetes treatment
Novo Nordisk and Viatris Settle Patent Dispute Over Ozempic and Wegovy, Keeping Generic Entry Date Undisclosed
Novo Nordisk, Viatris, Mylan Pharmaceuticals, Ozempic, Wegovy, Patent Dispute, Generic Entry Date, Settlement Agreement
Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing
Eli Lilly, obesity drug shortage, Mounjaro, Zepbound, Novo Nordisk, Wegovy, GLP-1 drugs, pharmaceutical manufacturing, weight loss drugs.
Novo Nordisk CEO Faces Senate Scrutiny Over High Prices of Ozempic and Wegovy
Novo Nordisk, Senate Hearing, Ozempic, Wegovy, Drug Prices, Pharmacy Benefit Managers (PBMs), Insurance Coverage, Healthcare System
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market
Novo Nordisk’s Wegovy Sales Shortfall: A Rare Setback for the Danish Drugmaker
Novo Nordisk, Wegovy, weight-loss drug, sales shortfall, stock performance, pharmaceutical industry
Novo Nordisk Withdraws FDA Submission for Wegovy’s Heart Failure Indication, Plans to Reapply Next Year
Novo Nordisk, Wegovy, FDA submission, heart failure, label expansion, regulatory delay
EU Panel Recommends Wegovy for Preventing Cardiac Events, Following FDA Lead
Wegovy, EU panel, FDA, cardiac events, weight loss, Novo Nordisk
Novo Nordisk’s Wegovy Receives UK Approval to Reduce Cardiovascular Risks in Overweight and Obese Adults
Wegovy, Novo Nordisk, UK approval, cardiovascular risks, weight loss, obesity, GLP-1 receptor agonist, semaglutide
Eli Lilly, Novo Nordisk Shares Fall as their weight-Loss drugs face competition
, Eli Lilly, Novo Nordisk, Roche, Obesity drugs, Weight-loss drug market, Stock market, Pharmaceutical competition, GLP-1 therapy, CT-996, Zepbound, Wegovy,